{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:28:50Z","timestamp":1740144530501,"version":"3.37.3"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T00:00:00Z","timestamp":1633132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T00:00:00Z","timestamp":1633132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Trajectory Analysis Project"},{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Akcea Therapeutics"},{"name":"Mitocon"},{"name":"Famiglie SMA"},{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In 2001, Fondazione Telethon and the Italian muscular dystrophy patient organisation Unione Italiana Lotta alla Distrofia Muscolare joined their efforts to design and launch a call for grant applications specifically dedicated to clinical projects in the field of neuromuscular disorders. This strategic initiative, run regularly over the years and still ongoing, aims at supporting research with impact on the daily life of people with a neuromuscular condition and is centred on macro-priorities identified by the patient organisation. It is investigator-driven, and all proposals are peer-reviewed for quality and feasibility. Over the years, this funding program contributed to strengthening the activities of the Italian neuromuscular clinical network, reaching many achievements in healthcare research. Moreover, it has been an enabling factor for innovative therapy experimentation at international level and prepared the clinical ground to make therapies available to Italian patients. The ultimate scope of healthcare research is to ameliorate the delivery of care. In this paper, the achievements of the funded studies are analysed also from this viewpoint, to ascertain to which extent they have fulfilled the original goals established by the patient organisation. The evidence presented indicates that this has been a highly fruitful program. Factors that contributed to its success, lessons learned, challenges, and issues that remain to be addressed are discussed to provide practical examples of an experience that could inspire also other organizations active in the field of rare disease research.<\/jats:p>","DOI":"10.1186\/s13023-021-02047-1","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T14:45:42Z","timestamp":1633358742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fondazione Telethon and Unione Italiana Lotta alla Distrofia Muscolare, a successful partnership for neuromuscular healthcare research of value for patients"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3065-975X","authenticated-orcid":false,"given":"Anna","family":"Ambrosini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danila","family":"Baldessari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Battaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Beltrami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Merico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Rasconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Monaco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,2]]},"reference":[{"issue":"3","key":"2047_CR1","doi-asserted-by":"publisher","first-page":"289","DOI":"10.15252\/emmm.201607293","volume":"9","author":"L Monaco","year":"2017","unstructured":"Monaco L, Faccio L. Patient-driven search for rare disease therapies: the Fondazione Telethon success story and the strategy leading to Strimvelis. EMBO Mol Med. 2017;9(3):289\u201392.","journal-title":"EMBO Mol Med"},{"key":"2047_CR2","unstructured":"EMA authorisation of Libmeldy, Autologous CD34+ cells encoding ARSA gene. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/libmeldy. Accessed 30 July 2021."},{"issue":"5","key":"2047_CR3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/WCO.0000000000000474","volume":"30","author":"D Pareyson","year":"2017","unstructured":"Pareyson D, Saveri P, Pisciotta C. New developments in Charcot\u2013Marie\u2013Tooth neuropathy and related diseases. Curr Opin Neurol. 2017;30(5):471\u201380.","journal-title":"Curr Opin Neurol"},{"issue":"10213","key":"2047_CR4","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","volume":"394","author":"E Mercuri","year":"2019","unstructured":"Mercuri E, B\u00f6nnemann CG, Muntoni F. Muscular dystrophies. Lancet. 2019;394(10213):2025\u201338.","journal-title":"Lancet"},{"key":"2047_CR5","unstructured":"Centro clinico NEMO website. https:\/\/centrocliniconemo.it\/. Accessed 30 July 2021."},{"key":"2047_CR6","unstructured":"Centro clinico NEMO annual Impact Report 2019. https:\/\/f.hubspotusercontent00.net\/hubfs\/4358056\/Bilancio%20Sociale%202019.pdf. Accessed 30 July 2021."},{"key":"2047_CR7","unstructured":"Web of Science website. https:\/\/clarivate.com\/webofsciencegroup\/. Accessed 26 Feb 2021."},{"key":"2047_CR8","unstructured":"Europe PubMed Central website. https:\/\/europepmc.org\/. Accessed 26 Feb 2021."},{"issue":"9","key":"2047_CR9","doi-asserted-by":"publisher","first-page":"e1002541","DOI":"10.1371\/journal.pbio.1002541","volume":"14","author":"BI Hutchins","year":"2016","unstructured":"Hutchins BI, Yuan X, Anderson JM, Santangelo GM. Relative citation ratio (RCR): a new metric that uses citation rates to measure influence at the article level. PLoS Biol. 2016;14(9):e1002541.","journal-title":"PLoS Biol"},{"key":"2047_CR10","unstructured":"NIH iCite website. https:\/\/icite.od.nih.gov\/analysis . Accessed 30 July 2021."},{"key":"2047_CR11","unstructured":"DORA website. http:\/\/www.ascb.org\/dora\/. Accessed 30 July 2021."},{"issue":"3","key":"2047_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.nmd.2007.11.008","volume":"18","author":"L Padua","year":"2008","unstructured":"Padua L, Pareyson D, Aprile I, Cavallaro T, Quattrone A, Rizzuto N, et al. Natural history of CMT1A including QoL: a 2-year prospective study. Neuromuscul Disord. 2008;18(3):199\u2013203.","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"2047_CR13","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1212\/WNL.0000000000001303","volume":"84","author":"A Graziano","year":"2015","unstructured":"Graziano A, Bianco F, D\u2019Amico A, Moroni I, Messina S, Bruno C, et al. Prevalence of congenital muscular dystrophy in Italy: a population study. Neurology. 2015;84(9):904\u201311.","journal-title":"Neurology"},{"issue":"7","key":"2047_CR14","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1007\/s00415-015-7757-9","volume":"262","author":"F Fattori","year":"2015","unstructured":"Fattori F, Maggi L, Bruno C, Cassandrini D, Codemo V, Catteruccia M, et al. Centronuclear myopathies: genotype-phenotype correlation and frequency of defined genetic forms in an Italian cohort. J Neurol. 2015;262(7):1728\u201340.","journal-title":"J Neurol"},{"issue":"4\u20135","key":"2047_CR15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.nmd.2016.02.008","volume":"26","author":"M Mancuso","year":"2016","unstructured":"Mancuso M, Orsucci D, Angelini C, Bertini E, Carelli V, Comi GP, et al. \u201cMitochondrial neuropathies\u201d: a survey from the large cohort of the Italian Network. Neuromuscul Disord. 2016;26(4\u20135):272\u20136.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"2047_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/mus.25192","volume":"55","author":"F Magri","year":"2017","unstructured":"Magri F, Nigro V, Angelini C, Mongini T, Mora M, Moroni I, et al. The Italian limb girdle muscular dystrophy registry: relative frequency, clinical features, and differential diagnosis. Muscle Nerve. 2017;55(1):55\u201368.","journal-title":"Muscle Nerve"},{"issue":"1","key":"2047_CR17","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13023-018-0863-x","volume":"13","author":"G Astrea","year":"2018","unstructured":"Astrea G, Romano A, Angelini C, Antozzi CG, Barresi R, Battini R, et al. Broad phenotypic spectrum and genotype-phenotype correlations in GMPPB-related dystroglycanopathies: an Italian cross-sectional study. Orphanet J Rare Dis. 2018;13(1):170.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"2047_CR18","doi-asserted-by":"publisher","first-page":"e696","DOI":"10.1212\/WNL.0000000000006050","volume":"91","author":"M Pane","year":"2018","unstructured":"Pane M, Palermo C, Messina S, Sansone VA, Bruno C, Catteruccia M, et al. An observational study of functional abilities in infants, children, and adults with type 1 SMA. Neurology. 2018;91(8):e696\u2013703.","journal-title":"Neurology"},{"issue":"11","key":"2047_CR19","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.nmd.2019.09.010","volume":"29","author":"G Coratti","year":"2019","unstructured":"Coratti G, Brogna C, Norcia G, Ricotti V, Abbott L, D\u2019Amico A, et al. Longitudinal natural history in young boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2019;29(11):857\u201362.","journal-title":"Neuromuscul Disord"},{"key":"2047_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10144-7","author":"L Vercelli","year":"2020","unstructured":"Vercelli L, Mele F, Ruggiero L, Sera F, Tripodi S, Ricci G, et al. A 5-year clinical follow-up study from the Italian National Registry for FSHD. J Neurol. 2020. https:\/\/doi.org\/10.1007\/s00415-020-10144-7.","journal-title":"J Neurol"},{"issue":"2","key":"2047_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s40478-014-0100-3","volume":"11","author":"M Savarese","year":"2014","unstructured":"Savarese M, Di Fruscio G, Mutarelli M, Torella A, Magri F, Santorelli FM, et al. MotorPlex provides accurate variant detection across large muscle genes both in single myopathic patients and in pools of DNA samples. Acta Neuropathol Commun. 2014;11(2):100.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"2047_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1212\/WNL.0000000000002800","volume":"87","author":"M Savarese","year":"2016","unstructured":"Savarese M, Di Fruscio G, Torella A, Fiorillo C, Magri F, Fanin M, et al. The genetic basis of undiagnosed muscular dystrophies and myopathies: results from 504 patients. Neurology. 2016;87(1):71\u20136.","journal-title":"Neurology"},{"issue":"8","key":"2047_CR23","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2174\/1566524014666141010154205","volume":"14","author":"D Pareyson","year":"2014","unstructured":"Pareyson D, Saveri P, Piscosquito G. Charcot\u2013Marie\u2013Tooth disease and related hereditary neuropathies: from gene function to associated phenotypes. Curr Mol Med. 2014;14(8):1009\u201333.","journal-title":"Curr Mol Med"},{"issue":"1","key":"2047_CR24","doi-asserted-by":"publisher","first-page":"21648","DOI":"10.1038\/s41598-020-78578-7","volume":"10","author":"G Ricci","year":"2020","unstructured":"Ricci G, Mele F, Govi M, Ruggiero L, Sera F, Vercelli L, et al. Large genotype-phenotype study in carriers of D4Z4 borderline alleles provides guidance for facioscapulohumeral muscular dystrophy diagnosis. Sci Rep. 2020;10(1):21648.","journal-title":"Sci Rep"},{"issue":"4","key":"2047_CR25","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/13506129.2020.1794807","volume":"27","author":"M Russo","year":"2020","unstructured":"Russo M, Obici L, Bartolomei I, Cappelli F, Luigetti M, Fenu S, et al. ATTRv amyloidosis Italian Registry: clinical and epidemiological data. Amyloid. 2020;27(4):259\u201365.","journal-title":"Amyloid"},{"key":"2047_CR26","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s13023-020-01633-z","volume":"15","author":"M Grandis","year":"2020","unstructured":"Grandis M, Obici L, Luigetti M, Briani C, Benedicenti F, Bisogni G, et al. Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus. Orphanet J Rare Dis. 2020;15:348.","journal-title":"Orphanet J Rare Dis"},{"key":"2047_CR27","unstructured":"TREAT-NMD website. https:\/\/treat-nmd.org\/. Accessed 30 July 2021."},{"issue":"8","key":"2047_CR28","doi-asserted-by":"publisher","first-page":"e0160195","DOI":"10.1371\/journal.pone.0160195","volume":"11","author":"E Mercuri","year":"2016","unstructured":"Mercuri E, Coratti G, Messina S, Ricotti V, Baranello G, D\u2019Amico A, et al. Revised North Star Ambulatory Assessment for young boys with duchenne muscular dystrophy. PLoS ONE. 2016;11(8):e0160195.","journal-title":"PLoS ONE"},{"issue":"3","key":"2047_CR29","doi-asserted-by":"publisher","first-page":"e0151445","DOI":"10.1371\/journal.pone.0151445","volume":"11","author":"ES Mazzone","year":"2016","unstructured":"Mazzone ES, Coratti G, Sormani MP, Messina S, Pane M, D\u2019Amico A, et al. Timed rise from floor as a predictor of disease progression in duchenne muscular dystrophy: an observational study. PLoS ONE. 2016;11(3):e0151445.","journal-title":"PLoS ONE"},{"key":"2047_CR30","unstructured":"Inherited Neuropathy Consortium (INC) website. https:\/\/www.rarediseasesnetwork.org\/cms\/inc. Accessed 30 July 2021."},{"issue":"2","key":"2047_CR31","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/ene.14074","volume":"27","author":"L Mori","year":"2020","unstructured":"Mori L, Signori A, Prada V, Pareyson D, Piscosquito G, Padua L, et al. Treadmill training in patients affected by Charcot\u2013Marie\u2013Toothneuropathy: results of a multicenter, prospective, randomized, single-blind, controlled study. Eur J Neurol. 2020;27(2):280\u20137.","journal-title":"Eur J Neurol"},{"issue":"9","key":"2047_CR32","doi-asserted-by":"publisher","first-page":"e884","DOI":"10.1212\/WNL.0000000000009035","volume":"94","author":"V Fridman","year":"2020","unstructured":"Fridman V, Sillau S, Acsadi G, Bacon C, Dooley K, Burns J, et al. A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores. Neurology. 2020;94(9):e884\u201396.","journal-title":"Neurology"},{"issue":"11","key":"2047_CR33","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/dmcn.12213","volume":"55","author":"A Mayhew","year":"2013","unstructured":"Mayhew A, Mazzone ES, Eagle M, Duong T, Ash M, Decostre V, et al. Development of the performance of the upper limb module for Duchenne muscular dystrophy. Performance of the Upper Limb Working Group. Dev Med Child Neurol. 2013;55(11):1038\u201345.","journal-title":"Dev Med Child Neurol"},{"issue":"5","key":"2047_CR34","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/dmcn.14361","volume":"62","author":"AG Mayhew","year":"2020","unstructured":"Mayhew AG, Coratti G, Mazzone ES, Klingels K, James M, Pane M, et al. Performance of upper limb module for Duchenne muscular dystrophy. Dev Med Child Neurol. 2020;62(5):633\u20139.","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"2047_CR35","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/dmcn.13277","volume":"59","author":"K Klingels","year":"2017","unstructured":"Klingels K, Mayhew AG, Mazzone ES, Duong T, Decostre V, Werlauff U, et al. Development of a patient-reported outcome measure for upper limb function in Duchenne muscular dystrophy: DMD Upper Limb PROM. Dev Med Child Neurol. 2017;59(2):224\u201331.","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"2047_CR36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.24555","volume":"79","author":"JR Mendell","year":"2016","unstructured":"Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016;79(2):257\u201371.","journal-title":"Ann Neurol"},{"issue":"4","key":"2047_CR37","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.nmd.2019.02.002","volume":"29","author":"V Ricotti","year":"2019","unstructured":"Ricotti V, Selby V, Ridout D, Domingos J, Decostre V, Mayhew A, et al. Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: a prospective multicentre study. Neuromuscul Disord. 2019;29(4):261\u20138.","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"2047_CR38","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.nmd.2015.07.009","volume":"25","author":"M Pane","year":"2015","unstructured":"Pane M, Fanelli L, Mazzone ES, Olivieri G, D\u2019Amico A, Messina S, et al. Benefits of glucocorticoids in non-ambulant boys\/men with Duchenne muscular dystrophy: a multicentric longitudinal study using the performance of upper limb test. Neuromuscul Disord. 2015;25(10):749\u201353.","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"2047_CR39","doi-asserted-by":"publisher","first-page":"e0199223","DOI":"10.1371\/journal.pone.0199223","volume":"13","author":"M Pane","year":"2018","unstructured":"Pane M, Coratti G, Brogna C, Mazzone ES, Mayhew A, Fanelli L, et al. Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. PLoS One. 2018;13(6):e0199223.","journal-title":"PLoS One."},{"issue":"9","key":"2047_CR40","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1111\/j.1468-1331.2010.02992.x","volume":"17","author":"VA Sansone","year":"2010","unstructured":"Sansone VA, Panzeri M, Montanari M, Apolone G, Gandossini S, Rose MR, et al. Italian validation of INQoL, a quality of life questionnaire for adults with muscle diseases. Eur J Neurol. 2010;17(9):1178\u201387.","journal-title":"Eur J Neurol"},{"issue":"1","key":"2047_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/mus.24503","volume":"52","author":"L Magliano","year":"2015","unstructured":"Magliano L, Patalano M, Alessandra Sagliocchi A, Scutifero M, Zaccaro A, D\u2019Angelo MG, et al. Burden, professional support, and social network in families of children and young adults with muscular dystrophies. Muscle Nerve. 2015;52(1):13\u201321.","journal-title":"Muscle Nerve"},{"issue":"3","key":"2047_CR42","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/mus.20937","volume":"37","author":"A Martinuzzi","year":"2008","unstructured":"Martinuzzi A, Liava A, Trevisi E, Frare M, Tonon C, Malucelli E, et al. Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle\u2019s disease. Muscle Nerve. 2008;37(3):350\u20137.","journal-title":"Muscle Nerve"},{"issue":"4","key":"2047_CR43","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S1474-4422(11)70025-4","volume":"10","author":"D Pareyson","year":"2011","unstructured":"Pareyson D, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, et al. Ascorbic acid in Charcot\u2013Marie\u2013Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol. 2011;10(4):320\u20138.","journal-title":"Lancet Neurol"},{"issue":"11","key":"2047_CR44","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1038\/mt.2014.138","volume":"22","author":"G Parenti","year":"2014","unstructured":"Parenti G, Fecarotta S, La Marca G, Rossi B, Ascione S, Donati MA, et al. A chaperone enhances blood \u03b1-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy. Mol Ther. 2014;22(11):2004\u201312.","journal-title":"Mol Ther"},{"key":"2047_CR45","first-page":"139194","volume":"66","author":"L Merlini","year":"2011","unstructured":"Merlini L, Sabatelli P, Armaroli A, Gnudi S, Angelin A, Grumati P, et al. Cyclosporine A in Ullrich congenital muscular dystrophy: long-term results. Oxid Med Cell Longev. 2011;66:139194.","journal-title":"Oxid Med Cell Longev"},{"key":"2047_CR46","unstructured":"Registro Italiano dei pazienti con malattie neuromuscolari website. http:\/\/www.registronmd.it\/?page_id=461. Accessed 30 July 2021."},{"key":"2047_CR47","unstructured":"European General Data protection Regulation website. https:\/\/gdpr.eu. Accessed 30 July 2021."},{"issue":"1","key":"2047_CR48","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13023-018-0918-z","volume":"13","author":"A Ambrosini","year":"2018","unstructured":"Ambrosini A, Calabrese D, Avato FM, Catania F, Cavaletti G, Pera MC, et al. The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage. Orphanet J Rare Dis. 2018;13(1):176.","journal-title":"Orphanet J Rare Dis"},{"issue":"24","key":"2047_CR49","doi-asserted-by":"publisher","first-page":"e3180","DOI":"10.1212\/WNL.0000000000010860","volume":"95","author":"C Pisciotta","year":"2020","unstructured":"Pisciotta C, Calabrese D, Santoro L, Tramacere I, Manganelli F, Fabrizi GM, et al. Pregnancy in Charcot\u2013Marie\u2013Tooth disease: data from the Italian CMT national registry. Neurology. 2020;95(24):e3180\u20139.","journal-title":"Neurology"},{"issue":"1","key":"2047_CR50","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13023-021-01812-6","volume":"16","author":"L Magliano","year":"2021","unstructured":"Magliano L, Obici L, Sforzini C, Mazzeo A, Russo M, Cappelli F, et al. Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy. Orphanet J Rare Dis. 2021;16(1):163.","journal-title":"Orphanet J Rare Dis"},{"key":"2047_CR51","unstructured":"Registro italiano dei pazienti mitocondriali website. https:\/\/www.mitocon.it\/registro-pazienti\/. Accessed 30 July 2021."},{"issue":"4","key":"2047_CR52","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00415-019-09219-x","volume":"266","author":"M Filosto","year":"2019","unstructured":"Filosto M, Cotti Piccinelli S, Lamperti C, Mongini T, Servidei S, et al. Muscle pain in mitochondrial diseases: a picture from the Italian network. Neurol. 2019;266(4):953\u20139.","journal-title":"Neurol"},{"issue":"8","key":"2047_CR53","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S1474-4422(16)30035-7","volume":"15","author":"V Straub","year":"2016","unstructured":"Straub V, Balabanov P, Bushby K, Ensini M, Goemans N, De Luca A, et al. Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. Lancet Neurol. 2016;15(8):882\u201390.","journal-title":"Lancet Neurol"},{"key":"2047_CR54","unstructured":"Mercuri E, Signorovitch JE, Swallow E, Song J, Ward SJ; DMD Italian Group; Trajectory Analysis Project (cTAP). Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy. Neuromuscul Disord. 2016;26(9):576\u201383 [Corrigendum Neuromuscular Disorders 2017 May;27(5):e1]."},{"key":"2047_CR55","doi-asserted-by":"crossref","unstructured":"Brogna C, Coratti G, Pane M, Ricotti V, Messina S, D'Amico A, et al. Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. PLoS ONE. 2019;14(6):e0218683. [PLoS ONE. Correction: 2019;14(7):e0220714].","DOI":"10.1371\/journal.pone.0218683"},{"issue":"10","key":"2047_CR56","doi-asserted-by":"publisher","first-page":"e1381","DOI":"10.1212\/WNL.0000000000010170","volume":"95","author":"N Goemans","year":"2020","unstructured":"Goemans N, Signorovitch J, Sajeev G, Yao Z, Gordish-Dressman H, et al. Suitability of external controls for drug evaluation in Duchenne muscular dystrophy. Neurology. 2020;95(10):e1381\u201391.","journal-title":"Neurology"},{"issue":"8","key":"2047_CR57","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","volume":"22","author":"CH Wang","year":"2007","unstructured":"Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027\u201349.","journal-title":"J Child Neurol"},{"issue":"1","key":"2047_CR58","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77\u201393.","journal-title":"Lancet Neurol"},{"issue":"2","key":"2047_CR59","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1474-4422(09)70272-8","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9(2):177\u201389.","journal-title":"Lancet Neurol"},{"key":"2047_CR60","unstructured":"EURO-NMD European Reference network website: European Reference Network\u2014EURO-NMD\u2014European Reference Network for Neuromuscular Diseases (ern-euro-nmd.eu). Accessed 30 July 2021."},{"issue":"1","key":"2047_CR61","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13023-020-01514-5","volume":"15","author":"KL Miller","year":"2020","unstructured":"Miller KL, Mueller C, Liu G, Miller Needleman KI, Maynard J. FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development. Orphanet J Rare Dis. 2020;15(1):234.","journal-title":"Orphanet J Rare Dis"},{"issue":"15","key":"2047_CR62","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2288-15-4","volume":"9","author":"JA Sacrist\u00e1n","year":"2015","unstructured":"Sacrist\u00e1n JA. Clinical research and medical care: towards effective and complete integration. BMC Med Res Methodol. 2015;9(15):4.","journal-title":"BMC Med Res Methodol"},{"key":"2047_CR63","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12913-016-1292-y","volume":"16","author":"N Kristensen","year":"2016","unstructured":"Kristensen N, Nymann C, Konradsen H. Implementing research results in clinical practice\u2014the experiences of healthcare professionals. BMC Health Serv Res. 2016;16:48.","journal-title":"BMC Health Serv Res"},{"issue":"11","key":"2047_CR64","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/14737159.2019.1672540","volume":"19","author":"R Horton","year":"2019","unstructured":"Horton R, Lucassen A. Genomic testing in healthcare: a hybrid space where clinical practice and research need to co-exist. Expert Rev Mol Diagnost. 2019;19(11):963\u20137.","journal-title":"Expert Rev Mol Diagnost"},{"issue":"5","key":"2047_CR65","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.nmd.2017.02.006","volume":"27","author":"A D'Amico","year":"2017","unstructured":"D\u2019Amico A, Catteruccia M, Baranello G, Politano L, Govoni A, Previtali SC, et al. Diagnosis of Duchenne Muscular Dystrophy in Italy in the last decade: critical issues and areas for improvements. Neuromuscul Disord. 2017;27(5):447\u201351.","journal-title":"Neuromuscul Disord"},{"issue":"11","key":"2047_CR66","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/genes9110524","volume":"9","author":"T Giugliano","year":"2018","unstructured":"Giugliano T, Savarese M, Garofalo A, Picillo E, Fiorillo C, D\u2019Amico A, et al. Copy number variants account for a tiny fraction of undiagnosed myopathic patients. Genes. 2018;9(11):524.","journal-title":"Genes"},{"issue":"3","key":"2047_CR67","doi-asserted-by":"publisher","first-page":"e0230677","DOI":"10.1371\/journal.pone.0230677","volume":"15","author":"MC Pera","year":"2020","unstructured":"Pera MC, Coratti G, Berti B, D\u2019Amico A, Sframeli M, Albamonte E, et al. Diagnostic journey in spinal muscular atrophy: Is it still an odyssey? PLoS ONE. 2020;15(3):e0230677.","journal-title":"PLoS ONE"},{"issue":"1","key":"2047_CR68","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13023-019-1103-8","volume":"14","author":"A Ambrosini","year":"2019","unstructured":"Ambrosini A, Quinlivan R, Sansone VA, Meijer I, Schrijvers G, Tibben A, et al. \u201cBe an ambassador for change that you would like to see\u201d: a call to action to all stakeholders for co-creation in healthcare and medical research to improve quality of life of people with a neuromuscular disease. Orphanet J Rare Dis. 2019;14(1):126.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2047_CR69","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10072-018-3622-9","volume":"40","author":"VA Sansone","year":"2019","unstructured":"Sansone VA, Albamonte E, Salmin F, Casiraghi J, Pirola A, Bettinelli M, et al. Intrathecal nusinersen treatment for SMA in a dedicated neuromuscular clinic: an example of multidisciplinary and integrated care. Neurol Sci. 2019;40(2):327\u201332.","journal-title":"Neurol Sci"},{"issue":"12","key":"2047_CR70","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.nmd.2017.09.006","volume":"27","author":"S Messina","year":"2017","unstructured":"Messina S, Pane M, Sansone V, Bruno C, Catteruccia M, Vita G, et al. Expanded access program with Nusinersen in SMA type I in Italy: strengths and pitfalls of a successful experience. Neuromuscul Disord. 2017;27(12):1084\u20136.","journal-title":"Neuromuscul Disord"},{"key":"2047_CR71","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12961-018-0335-8","volume":"16","author":"Y Cartier","year":"2018","unstructured":"Cartier Y, Creatore MI, Hoffmann SJ, Potvin L. Priority-setting in public health research funding organisations: an exploratory qualitative study among five high-profile funders. Health Res Policy Syst. 2018;16:53.","journal-title":"Health Res Policy Syst"},{"issue":"1","key":"2047_CR72","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-021-01687-7","volume":"16","author":"H Lochm\u00fcller","year":"2021","unstructured":"Lochm\u00fcller H, Ramirez AN, Kakkis E. Disease monitoring programs of rare genetic diseases: transparent data sharing between academic and commercial stakeholders. Orphanet J Rare Dis. 2021;16(1):141.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02047-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-02047-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02047-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T18:28:25Z","timestamp":1633372105000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-02047-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,2]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2047"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-02047-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2021,10,2]]},"assertion":[{"value":"14 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"408"}}